|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Seplat Energy PLC - Nigeria-focused energy supplier - Announces first gas from the ANOH project, with four upstream wells brought online, having been on standby since November. ANOH Gas Processing Co has started gas supply to the Indorama gas export pipeline following regulatory approval on Friday. Seplat says wet gas production has been stabilising, with 40 million to 52 million standard cubic feet of processed gas per day delivered from the ANOH gas plant to the Indorama Petrochemical Plant. Condensate production has reached between 2,000 and 2,500 barrels of oil equivalent per day. Seplat expects this to increase as the plant ramps up to design capacity. Adds that preparations are underway to start sales of processed gas to the Nigeria LNG plant, with an offtake agreement expected to support the ANOH plant to scale production towards its full 300 MMscfd design capacity. ‘This is our third major gas processing facility onshore and increases our joint venture gross gas processing capacity onshore to over 850 MMscfd,’ says Chief Executive Officer Roger Brown. ‘ANOH will provide material income streams for Seplat, reduce our carbon intensity and contribute significantly to the 2030 production target of 200 kboepd, set at our recent [capital markets day].’ ---------- Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company - Says it made excellent progress during 2025, including in the development of its pre|CISION platform and in raising £22.5 million in equity to support its research & development programmes. Notes ‘highly encouraging efficacy and safety data’ for salivary gland cancer patients in its faridoxorubicin (AVA6000) programme, which has continued to enroll patients in the phase 1b expansion cohorts. Company anticipates multiple data updates in the salivary gland and breast cancer groups. Expects clinical testing for the FAP-Exd (AVA6103) programme to start in the first quarter. Advances in the pre|CISION intellectual property portfolio include ‘the sustained release mechanism of payload delivery, piloted in the AVA6103 program’. Cash balance totals £16.9 million as of December 31, which Avacta says provides a runway into the third quarter. Looking ahead, it says active interaction continues with potential partners for both programmes, and that the start of the FAP-Exd clinical trial is still ‘of interest in the market’. ‘We continue to have multiple conversations with global pharmaceutical companies regarding our full pipeline,’ says CEO Christina Coughlin. ‘We are incredibly excited for the year ahead, which the board believes will be a transformative period for the company, patients and our shareholders.’ ---------- Treatt PLC - Suffolk, England-based extracts and ingredients manufacturer - Reports results for the year ended September 30. Revenue decreases 12% to £132.5 million from £150.2 million the year before. Pretax profit falls 61% to £7.0 million from £17.9 million. Declares 3.00 pence per share final dividend, down from 5.81p. This cuts the total dividend by 33% to 5.60p from 8.41p. Treatt ‘will seek to increase future dividends as profits recover’. Company says the year featured ‘weaker US market conditions, driven by consumer demand and tariff uncertainty, coupled with citrus market headwinds impacting our headline financial performance.’ ‘Despite a challenging year, Treatt has many strengths to build upon and to restore its performance, including...a strong brand with a reputation for quality products in both FMCG and flavour house markets, a strong balance sheet with minimal debt, and modern facilities with the capacity for growth and readiness to take advantage of global changing markets,’ says Chair Vijay Thakrar. Separately, Treatt says it has entered a customary relationship agreement with major shareholder Dohler Finance Management BV. All transactions between the two ‘will be conducted at arm’s length and on normal commercial terms’, and Dohler agrees not to take any action or propose any shareholder resolution that would prevent the company from complying with its regulatory obligations. Dohler also has the right to nominate a candidate to Treatt’s board, with Helga Moelschl to join on February 1 as a non-executive director as a result. The deal will terminate if Dohler’s shareholding falls below 25%, Treatt has. ---------- Team Internet Group PLC - London-based internet services company - Announces a trading update for 2025. Expects to report gross revenue, net revenue and adjusted earnings before interest, tax, depreciation and amortisation towards the top end of analyst forecast ranges. These are for gross revenue between $371 million to $541 million, net revenue between $113 million and $134 million, and adjusted Ebitda between $40 million to $43 million. Team Internet says this is primarily driven by accelerated momentum in the Comparison and Domains, Identity & Software segments, along with a determined focus on cost discipline. Confirms that discussions regarding a potential sale of the DIS segment are progressing well, and ‘remains confident that any transaction would deliver a value-maximising outcome in excess of the group’s current market capitalisation.’ ‘2025 was an exceptionally challenging year for Team Internet,’ comments CEO Michael Riedl. ‘We faced a sharp contraction in revenue and significant Ebitda pressure, reflecting both adverse market conditions and the scale of change under way across our industry...Against this backdrop, the performance in the final quarter - and the group’s expectation to deliver earnings at the top end of market forecasts - is particularly significant.’ ---------- Kromek Group PLC - Sedgefield, England-based detection technology supplier - Reports results for the six months ended October 31. Revenue rises ‘substantially’ to £15.0 million from £3.7 million the previous year. Advanced Imaging revenue rises to £10.8 million from £1.7 million, while CBRN Detection revenue rises to £4.3 million from £2.0 million. Adjusted Ebitda totals £6.0 million, swinging from a £2.3 million loss. Kromek also swings to pretax profit of £3.1 million, from a £5.7 million loss. Company says the main contributor to growth was £8.3 million from its financial 2025 agreement with Siemens Healthineers AG, which enables the production of cadmium zinc telluride detectors for single-photon emission computed tomography applications. Says it remains confident in its full-year outlook and continues to perform in line with market expectations. ---------- Eagle Eye Solutions Group PLC - London-based provider of software-as-a-service marketing solutions - Says revenue for the six months to the end of December is £23.0 million, down 5% on-year from £24.2 million. Annual recurring revenue rises 3% to £42.2 million from £41.0 million, with first-half ARR ‘exceeding that achieved in the entirety of the prior year’, while adjusted Ebitda falls 28% to £4.3 million from £5.9 million. These figures include revenue from the firm’s Neptune Retail Solutions contract, which it lost in June. The adjusted Ebitda margin widens to 86% from 81%, exceeding Eagle Eye’s expectations due to its ‘ongoing SaaS transformation and cost optimisation’, which ‘will allow the board to upgrade profit expectations, while continuing to selectively invest in growth initiatives during Q3.’ Eagle Eye expects to deliver adjusted Ebitda for the full year ‘comfortably ahead’ of current market expectations, which is for adjusted Ebitda of £5.9 million. The market consensus for revenue is £45.1 million. Company also anticipates returning to double-digit revenue and Ebtida growth in financial 2027. Continues to guide for a 20% Ebitda margin run rate upon exiting the full year. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
